The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Prenatal Dexamethasone Treatment of Children at Risk for Congenital Adrenal Hyperplasia: The Swedish Experience and Standpoint
Abstract
Congenital adrenal hyperplasia (CAH) refers to rare (∼1:10,000), recessively inherited disorders of adrenal steroidogenesis. 21-Hydroxylase deficiency, the most common form, results in virilization of external genitalia in severely affected female fetuses. Prenatal treatment of CAH with dexamethasone (DEX) has been administered since the mid-1980s and is effective in reducing virilization in CAH-affected girls (1). The treatment has to be initiated early in pregnancy, before prenatal testing is possible. Consequently, seven of eight fetuses (all boys and CAH-unaffected girls) are treated in early pregnancy without any benefit of the treatment per se, until prenatal testing can determine the sex and diagnostic status at the end of the first trimester. CAH-affected girls are treated until term. Prenatal DEX treatment of fetuses at risk for CAH is controversial. Results from animal studies, as well as studies on prenatal glucocorticoid therapy in other contexts, have raised concerns regarding possible negative effects on behavioral and somatic development (2, 3). Adult corticosteroid-exposed rodent offspring are characterized by hypertension (via reduced nephron number); hyperinsulinemia and hyperglycemia (via permanently increased levels of the hepatic enzyme phosphoenolpyruvate carboxylase); fatty liver but not obesity when given a high-fat diet; and hyperactivity of the hypothalamic-pituitary-adrenal axis and altered affective behavior, reminiscent of anxiety, as well as impaired learning and memory functions. In the rhesus monkey, prenatal DEX during the last trimester resulted in offspring with elevated basal- and stress-stimulated cortisol at the age of 10 months as well as smaller hippocampal volume. In the African vervet monkey, high-dose DEX exposure (120–200 μg/kg) from midgestation until term resulted in offspring with an exaggerated cortisol response to stress already prepubertally, and adult animals exhibited hypertension, impaired glucose tolerance, and hyperinsulinemia (4). A long-term follow-up of individuals treated prenatally with betamethasone due to a risk of preterm birth shows that 30 yr after exposure the individuals exhibit insulin resistance, particularly in women, and 7% of the adults had elevated basal, morning cortisol levels (5). Other authors consider the prenatal treatment of CAH to be safe (1), but the recent Endocrine Society Guidelines state that such treatment should only be done within the frames of ethically approved clinical studies (6). The prenatal treatment of CAH is considered to be safe in the short-term perspective, although there are few long-term follow-up studies. In Sweden, prenatal treatment of CAH has been administered within the frameworks of a clinical study since 1999. The study, which is ongoing, is designed as a prospective, nonrandomized, multicenter trial in several participating European countries, including both follow-up of the mothers and long-term follow-up of the children. In Sweden, 31 cases have been enrolled during the last 10 yr. Hence, it will take several years before the first results from the long-term follow-up assessments will be available. We have also conducted retrospective follow-up studies of mothers and 43 children treated in Sweden and Norway during 1985–1995 (7–10). In summary, maternal side effects were such as can be expected with glucocorticoid/DEX treatment. Most of the maternal side effects seem to disappear after discontinuation of treatment, but in our experience, approximately 50% of the mothers treated during pregnancy and all mothers treated until term reported some type of discomfort that could be attributed to DEX. In general, treated children were born at term and were not small for gestational age. As a group, they did not exhibit teratogenous effects/gross malformations, although eight severe adverse events were noted in the treated group, compared with one in the control group. Three children failed to thrive during the first year of life; in addition, one of these children had a developmental delay; one had developmental delay and hypospadias; one had hydrocephalus; two girls were born small for gestational age, and one of these girls was later diagnosed with mental retardation; and one child had severe mood fluctuations that caused hospital admission. In the control group, only one child was admitted because of Down's syndrome. In the follow-up studies on the behavioral development of the 40 Swedish children, at a mean age of 11 yr, parent reports indicated good general adaptation, psychological well-being, and school performance in DEX-exposed children compared with nontreated controls. Direct neuropsychological assessments of the children showed normal results on measures of IQ, learning, and memory. However, an adverse effect was observed in the form of impaired verbal working memory in CAH-unaffected short-term-treated cases. The verbal working memory capacity correlated with the children's self-perception of
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Numerous studies (Table 8) have delineated adverse outcomes affecting brain, cardiovascular, renal, reproductive, thyroid and metabolic functions in non-human mammalian species exposed to glucocorticoids in utero (reviewed in (375)).”
From Congenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management (2022) · cites this paper as [375]
In the citing paper
“Endocrine societies and others have stated that the treatment is experimental and should only be performed in centers taking part in long-term research studies of these treated pregnancies (134,328,375,377,447).”
From Congenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management (2022) · cites this paper as [375]
Citations
Cites
Speiser, P. W., Azziz, R., Baskin, L. S., Ghizzoni, L., Hensle, T. W., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Montori, V. M., Oberfield, S. E., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2631 · Cited by 1,468 · cited 5×
“If further treatment is initiated in other centers, we wish to stress that the minimal requirement should be to follow the Paediatric Endocrine Society/European Society for Paediatric Endocrinology consensus statement from 2002 (11) and the more recent guidelines from The Endocrine Society (6), i.”
BackgroundInfluentialPrenatal glucocorticoids and long-term programming
Seckl (2004) · European Journal of Endocrinology · doi:10.1530/eje.0.151u049 · Cited by 825
Dalziel, S. R., Walker, N. K., Parag, V., Mantell, C., Rea, H. H., Rodgers, A., & Harding, J. E. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66617-2 · Cited by 461
(2002) · Hormone Research in Paediatrics · doi:10.1159/000065490 · Cited by 458
Joint LWPES/ESPE CAH Working Group (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020611 · Cited by 332
PW, S., W, A., RJ, A., LS, B., GS, C., DP, M., HFL, M.-B., WL, M., MH, M., SE, O., et al. (2019) · Yearbook of Paediatric Endocrinology · doi:10.1530/ey.16.8.5 · Cited by 300
de Vries, A., Holmes, M. C., Heijnis, A., Seier, J. V., Heerden, J., Louw, J., Wolfe-Coote, S., Meaney, M. J., Levitt, N. S., & Seckl, J. R. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30982 · Cited by 241
Hirvikoski, T., Nordenström, A., Lindholm, T., Lindblad, F., Ritzén, E. M., Wedell, A., & Lajic, S. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1340 · Cited by 228
Self-citationLong-Term Somatic Follow-Up of Prenatally Treated Children with Congenital Adrenal Hyperplasia1
Lajic, S., Wedell, A., Bui, T.-H., Ritzén, E. M., & Holst, M. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.11.5233 · Cited by 164
Self-citationHirvikoski, T., Nordenström, A., Lindholm, T., Lindblad, F., Ritzén, E. M., & Lajić, S. (2008) · European Journal of Endocrinology · doi:10.1530/eje-08-0280 · Cited by 104
Self-citationMiller, W. L. (1999) · The Journal of Urology · doi:10.1016/s0022-5347(05)68624-7 · Cited by 72
Nimkarn, S., & New, M. I. (2007) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0481 · Cited by 54
Hirvikoski, T., Lindholm, T., Lajic, S., & Nordenström, A. (2011) · Acta Paediatrica · doi:10.1111/j.1651-2227.2011.02260.x · Cited by 49
Self-citation
Cited by
Speiser, P. W., Arlt, W., Auchus, R. J., Baskin, L. S., Conway, G. S., Merke, D. P., Meyer-Bahlburg, H. F. L., Miller, W. L., Murad, M. H., Oberfield, S. E., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01865 · Cited by 1,234
Congenital adrenal hyperplasia
El-Maouche, D., Arlt, W., & Merke, D. P. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31431-9 · Cited by 669
Congenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management
Claahsen - van der Grinten, H. L., Speiser, P. W., Ahmed, S. F., Arlt, W., Auchus, R. J., Falhammar, H., Flück, C. E., Guasti, L., Huebner, A., Kortmann, B. B. M., et al. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab016 · Cited by 556
Self-citationGender dysphoria associated with disorders of sex development
Furtado, P. S., Moraes, F., Lago, R., de Barros, L. O., Toralles, M. B. P., & Barroso, U. (2012) · Nature Reviews Urology · doi:10.1038/nrurol.2012.182 · Cited by 117
Tardy-Guidollet, V., Menassa, R., Costa, J.-M., David, M., Bouvattier-Morel, C., Baumann, C., Houang, M., Lorenzini, F., Philip, N., Odent, S., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-2895 · Cited by 96
Metadata
- Authors
- Hirvikoski, T., Nordenström, A., Wedell, A., Ritzén, M., & Lajic, S.
- Affiliations
- Department of Molecular Medicine and Surgery, Centre for Molecular Medicine (T.H., A.N., A.W., S.L.), SE-17176 Stockholm, Sweden
- Department of Women's and Children's Health (M.R.), Karolinska Institutet/Karolinska University Hospital, SE-17176 Stockholm, Sweden
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2012-06-01
- Volume
- 97
- Issue
- 6
- Pages
- 1881-1883
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2043742190
- Cited by
- 80
- References
- 13
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 3 · 2023: 2 · 2022: 6 · 2021: 4 · 2020: 2 · 2019: 10 · 2018: 7 · 2017: 5 · 2016: 4 · 2015: 10 · 2014: 6 · 2013: 9 · 2012: 7
- FWCI
- 4.11
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Sexual Differentiation and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Birth, Development, and Health
- Keywords
- congenital adrenal hyperplasia, prenatal dexamethasone, 21-hydroxylase deficiency, fetal virilization, prenatal testing, hypothalamic-pituitary-adrenal axis, cortisol, insulin resistance, hypertension, glucocorticoid exposure, betamethasone, preterm birth
- MeSH terms
- Adrenal Hyperplasia, Congenital, Clinical Trials as Topic, Dexamethasone, Female, Glucocorticoids, Humans, Male, Pregnancy, Prenatal Exposure Delayed Effects, Risk Factors, Sweden, Virilism, Multicenter Studies as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.